Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 58

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder

Di Salvo, J., Nagabukuro, H., Wickham, L.A., Abbadie, C., DeMartino, J.A., Fitzmaurice, A., Gichuru, L., Kulick, A., Donnelly, M.J., Jochnowitz, N., Hurley, A.L., Pereira, A., Sanfiz, A., Veronin, G., Villa, K., Woods, J., Zamlynny, B., Zycband, E., Salituro, G.M., Frenkl, T., Weber, A.E., Edmondson, S.D., Struthers, M.·2017·The Journal of Pharmacology and Experimental Therapeutics
DOI 10.1124/jpet.116.237313
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1124/jpet.116.237313

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 54

  1. Abrams, 2007, Muscarinic receptor antagonists for overactive bladder, BJU Int, 100, 987, 10.1111/j.1464-410X.2007.07205.x · DOI · Paper page
  2. Abrams, 2002, The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society, Neurourol Urodyn, 21, 167, 10.1002/nau.10052 · DOI · Paper page
  3. Abrams, 2015, Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony), Eur Urol, 67, 577, 10.1016/j.eururo.2014.02.012 · DOI
  4. Ahlquist, 1948, A study of the adrenotropic receptors, Am J Physiol, 153, 586, 10.1152/ajplegacy.1948.153.3.586 · DOI
  5. Anderson, 1993, Pharmacology of lower urinary tract smooth muscles and penile erectile tissues, Pharmacol Rev, 45, 253, 10.1016/S0031-6997(25)00442-9 · DOI
  6. Andersson, 2015, Purinergic signalling in the urinary bladder, Auton Neurosci, 191, 78, 10.1016/j.autneu.2015.04.012 · DOI
  7. Andersson, 2004, Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence, Pharmacol Rev, 56, 581, 10.1124/pr.56.4.4 · DOI · Paper page
  8. Beckel, 2011, Neurophysiology of the lower urinary tract, Handb Exp Pharmacol, 202, 149, 10.1007/978-3-642-16499-6_8 · DOI
  9. Berkowitz, 1995, Distribution of beta 3-adrenoceptor mRNA in human tissues, Eur J Pharmacol, 289, 223, 10.1016/0922-4106(95)90098-5 · DOI
  10. Birder, 2007, Mechanisms of disease: involvement of the urothelium in bladder dysfunction, Nat Clin Pract Urol, 4, 46, 10.1038/ncpuro0672 · DOI · Paper page
  11. Bordicchia, 2014, Nebivolol induces, via β3 adrenergic receptor, lipolysis, uncoupling protein 1, and reduction of lipid droplet size in human adipocytes, J Hypertens, 32, 389, 10.1097/HJH.0000000000000024 · DOI
  12. Candelore, 1999, Potent and selective human beta(3)-adrenergic receptor antagonists, J Pharmacol Exp Ther, 290, 649, 10.1016/S0022-3565(24)34946-8 · DOI
  13. Cernecka, 2014, The odd sibling: features of β3-adrenoceptor pharmacology, Mol Pharmacol, 86, 479, 10.1124/mol.114.092817 · DOI
  14. Chapple, 2014, Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability, Neurourol Urodyn, 33, 17, 10.1002/nau.22505 · DOI
  15. Chapple, 2008, The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis, Eur Urol, 54, 543, 10.1016/j.eururo.2008.06.047 · DOI · Paper page
  16. Coyne, 2011, National community prevalence of overactive bladder in the United States stratified by sex and age, Urology, 77, 1081, 10.1016/j.urology.2010.08.039 · DOI · Paper page
  17. De Nunzio, 2015, The current indications and the benefits of combining a β3-agonist with an anticholinergic for the treatment of OAB, Curr Drug Targets, 16, 1198, 10.2174/1389450116666150806124345 · DOI
  18. Drake, 2008, Emerging drugs for treatment of overactive bladder and detrusor overactivity, Expert Opin Emerg Drugs, 13, 431, 10.1517/14728214.13.3.431 · DOI
  19. Edmondson, 2016, Discovery of vibegron: a potent and selective β3 adrenergic receptor agonist for the treatment of overactive bladder, J Med Chem, 59, 609, 10.1021/acs.jmedchem.5b01372 · DOI
  20. Ehlert, 2007, Neuronally released acetylcholine acts on the M2 muscarinic receptor to oppose the relaxant effect of isoproterenol on cholinergic contractions in mouse urinary bladder, J Pharmacol Exp Ther, 322, 631, 10.1124/jpet.107.121756 · DOI
  21. Ehlert, 2005, The M2 muscarinic receptor mediates contraction through indirect mechanisms in mouse urinary bladder, J Pharmacol Exp Ther, 313, 368, 10.1124/jpet.104.077909 · DOI
  22. Emorine, 1989, Molecular characterization of the human beta 3-adrenergic receptor, Science, 245, 1118, 10.1126/science.2570461 · DOI
  23. Fowler, 2008, The neural control of micturition, Nat Rev Neurosci, 9, 453, 10.1038/nrn2401 · DOI · Paper page
  24. Furuta, 2016, Combination therapy with β3 -adrenoceptor agonists and muscarinic acetylcholine receptor antagonists: Efficacy in rats with bladder overactivity, Int J Urol, 23, 425, 10.1111/iju.13066 · DOI
  25. Furuta, 2006, The promise of beta3-adrenoceptor agonists to treat the overactive bladder, Urol Clin North Am, 33, 539, 10.1016/j.ucl.2006.06.014 · DOI
  26. Gillespie, 2015, Beta adrenergic modulation of spontaneous microcontractions and electrical field-stimulated contractions in isolated strips of rat urinary bladder from normal animals and animals with partial bladder outflow obstruction, Naunyn Schmiedebergs Arch Pharmacol, 388, 719, 10.1007/s00210-015-1136-z · DOI
  27. Harmon, 2005, Beta-adrenergic receptor activation in immortalized human urothelial cells stimulates inflammatory responses by PKA-independent mechanisms, Cell Commun Signal, 3, 10, 10.1186/1478-811X-3-10 · DOI
  28. Irwin, 2006, Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study, Eur Urol, 50, 1306, 10.1016/j.eururo.2006.09.019 · DOI · Paper page
  29. Kullmann, 2011, Urothelial beta-3 adrenergic receptors in the rat bladder, Neurourol Urodyn, 30, 144, 10.1002/nau.20965 · DOI
  30. Kosilov, 2015, A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron, Arch Gerontol Geriatr, 61, 212, 10.1016/j.archger.2015.06.006 · DOI
  31. Lands, 1967, Differentiation of receptor systems activated by sympathomimetic amines, Nature, 214, 597, 10.1038/214597a0 · DOI · Paper page
  32. Limberg, 2010, β-Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder, Cell Tissue Res, 342, 295, 10.1007/s00441-010-1053-x · DOI
  33. Longnecker, 1966, A program for automated hematoxylin and eosin staining, Am J Clin Pathol, 45, 229, 10.1093/ajcp/45.2_ts.229 · DOI
  34. Maruyama, 2012, Effects of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, on bladder function in cynomolgus monkey, J Pharmacol Exp Ther, 342, 163, 10.1124/jpet.112.191783 · DOI
  35. Masunaga, 2010, The β3-adrenoceptor mediates the inhibitory effects of β-adrenoceptor agonists via the urothelium in pig bladder dome, Neurourol Urodyn, 29, 1320, 10.1002/nau.20838 · DOI
  36. Matsui, 2003, Increased relaxant action of forskolin and isoproterenol against muscarinic agonist-induced contractions in smooth muscle from M2 receptor knockout mice, J Pharmacol Exp Ther, 305, 106, 10.1124/jpet.102.044701 · DOI
  37. Matsumoto, 2012, Role of M2 and M3 muscarinic acetylcholine receptor subtypes in activation of bladder afferent pathways in spinal cord injured rats, Urology, 79, 1184.e15, 10.1016/j.urology.2012.01.022 · DOI
  38. Michel, 2016, β3-Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in a repositioning clinical drug development project, Pharmacol Ther, 159, 66, 10.1016/j.pharmthera.2016.01.007 · DOI
  39. Morgan, 2012, Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival, Drug Discov Today, 17, 419, 10.1016/j.drudis.2011.12.020 · DOI · Paper page
  40. Moyes, 2014, Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective β3 adrenergic receptor agonists for the treatment of overactive bladder, J Med Chem, 57, 1437, 10.1021/jm4017224 · DOI
  41. Nagabukuro, 2011, Comparative analysis of the effects of antimuscarinic agents on bladder functions in both nonhuman primates and rodents, J Pharmacol Exp Ther, 338, 220, 10.1124/jpet.111.179747 · DOI
  42. Nomiya, 2003, A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders, J Urol, 170, 649, 10.1097/01.ju.0000067621.62736.7c · DOI
  43. Ohlstein, 2012, A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder, Eur Urol, 62, 834, 10.1016/j.eururo.2012.05.053 · DOI
  44. Ohtake, 2007, Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents, Biol Pharm Bull, 30, 54, 10.1248/bpb.30.54 · DOI
  45. Otsuka, 2013, Expression of β-adrenoceptor subtypes in urothelium, interstitial cells and detrusor of the human urinary bladder, Low Urin Tract Symptoms, 5, 173, 10.1111/luts.12007 · DOI
  46. Otsuka, 2008, Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium, Naunyn Schmiedebergs Arch Pharmacol, 377, 473, 10.1007/s00210-008-0274-y · DOI
  47. Propping, 2013, Mucosa of human detrusor impairs contraction and β-adrenoceptor-mediated relaxation, BJU Int, 112, 1215, 10.1111/bju.12267 · DOI
  48. Rouget, 2014, Modulation of nerve-evoked contractions by β3-adrenoceptor agonism in human and rat isolated urinary bladder, Pharmacol Res, 80, 14, 10.1016/j.phrs.2013.12.006 · DOI
  49. Tallarida, 2001, Drug synergism: its detection and applications, J Pharmacol Exp Ther, 298, 865, 10.1016/S0022-3565(24)29450-7 · DOI · Paper page
  50. Thomas, 1993, Lack of beta 3-adrenergic receptor mRNA expression in adipose and other metabolic tissues in the adult human, Mol Pharmacol, 43, 343, 10.1016/S0026-895X(25)13619-5 · DOI
  51. Tyagi, 2010, Mirabegron, a β3-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder, IDrugs, 13, 713
  52. Uhlén, 2015, Proteomics. Tissue-based map of the human proteome, Science, 347, 1260419, 10.1126/science.1260419 · DOI · Paper page
  53. Ursino, 2009, The beta3-adrenoceptor as a therapeutic target: current perspectives, Pharmacol Res, 59, 221, 10.1016/j.phrs.2009.01.002 · DOI
  54. Wang, 1995, Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins, J Pharmacol Exp Ther, 273, 959, 10.1016/S0022-3565(25)09628-4 · DOI

Metadata

Authors
Di Salvo, J., Nagabukuro, H., Wickham, L. A., Abbadie, C., DeMartino, J. A., Fitzmaurice, A., Gichuru, L., Kulick, A., Donnelly, M. J., Jochnowitz, N., Hurley, A. L., Pereira, A., Sanfiz, A., Veronin, G., Villa, K., Woods, J., Zamlynny, B., Zycband, E., Salituro, G. M., Frenkl, T., Weber, A. E., Edmondson, S. D., & Struthers, M.
Venue
The Journal of Pharmacology and Experimental Therapeutics
Publisher
Elsevier BV
Published
2017-02
Volume
360
Issue
2
Pages
346-355
ISSN
0022-3565
DOI
10.1124/jpet.116.237313
Cited by
58
References
2
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.